Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking and Finance Review

Company

    GBAF Logo
    • About Us
    • Profile
    • Privacy & Cookie Policy
    • Terms of Use
    • Contact Us
    • Advertising
    • Submit Post
    • Latest News
    • Research Reports
    • Press Release
    • Awards▾
      • About the Awards
      • Awards TimeTable
      • Submit Nominations
      • Testimonials
      • Media Room
      • Award Winners
      • FAQ
    • Magazines▾
      • Global Banking & Finance Review Magazine Issue 79
      • Global Banking & Finance Review Magazine Issue 78
      • Global Banking & Finance Review Magazine Issue 77
      • Global Banking & Finance Review Magazine Issue 76
      • Global Banking & Finance Review Magazine Issue 75
      • Global Banking & Finance Review Magazine Issue 73
      • Global Banking & Finance Review Magazine Issue 71
      • Global Banking & Finance Review Magazine Issue 70
      • Global Banking & Finance Review Magazine Issue 69
      • Global Banking & Finance Review Magazine Issue 66
    Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

    Global Banking & Finance Review® is a leading financial portal and online magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management.
    Copyright © 2010-2026 GBAF Publications Ltd - All Rights Reserved. | Sitemap | Tags

    Editorial & Advertiser disclosure

    Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    Home > Finance > AstraZeneca sets out $15 billion China investment during Starmer visit
    Finance
    AstraZeneca sets out $15 billion China investment during Starmer visit

    Published by Global Banking and Finance Review

    Posted on January 29, 2026

    1 min read

    Last updated: January 29, 2026

    AstraZeneca sets out $15 billion China investment during Starmer visit - Finance news and analysis from Global Banking & Finance Review
    Tags:investmentfinancial communityinternational capital

    Quick Summary

    AstraZeneca plans to invest $15 billion in China by 2030, focusing on manufacturing and R&D, announced during UK PM Starmer's visit to Beijing.

    Table of Contents

    • AstraZeneca's Strategic Investment in China
    • Details of the Investment
    • Implications for UK-China Relations

    AstraZeneca sets out $15 billion China investment during Starmer visit

    AstraZeneca's Strategic Investment in China

    BEIJING/LONDON, Jan 29 (Reuters) - UK drugmaker AstraZeneca said on Thursday it would invest $15 billion in China through 2030 to expand medicines manufacturing and research and development, an announcement made during British Prime Minister Keir Starmer's visit to Beijing.

    Details of the Investment

    The announcement marks the biggest deal so far during the trip, as Britain seeks to strengthen ties with Beijing at a time of strained relations with Washington.

    Implications for UK-China Relations

    (Reporting by Andrew MacAskill in Beijing and Maggie Fick in LondonAdditional reporting by Andrew Silver in ShanghaiEditing by Muvija M)

    Key Takeaways

    • •AstraZeneca plans a $15 billion investment in China by 2030.
    • •The investment focuses on manufacturing and R&D expansion.
    • •Announcement coincides with UK PM Keir Starmer's visit to Beijing.
    • •This is the largest deal during the UK-China diplomatic trip.
    • •The move aims to strengthen UK-China relations amidst global tensions.

    Frequently Asked Questions about AstraZeneca sets out $15 billion China investment during Starmer visit

    1What is investment?

    Investment refers to the allocation of resources, usually money, in order to generate income or profit. It can involve purchasing assets, stocks, bonds, or real estate with the expectation of future returns.

    2What is research and development?

    Research and development (R&D) is a systematic approach to innovation and improvement in products or services. It involves investing time and resources to create new products or enhance existing ones.

    3What is international capital?

    International capital refers to financial assets that are transferred across national borders for investment purposes. It can include investments in foreign stocks, bonds, or direct investments in businesses.

    Why waste money on news and opinion when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    Previous Finance PostSwedish central bank keeps rates on hold at 1.75%, sees no change ahead
    Next Finance PostNorway orders $2 billion artillery system from South Korea's Hanwha Aerospace
    More from Finance

    Explore more articles in the Finance category

    UK's FTSE 100 rebounds as financial, commodity stocks gain
    Morning Bid: Mixed megacaps and Tehran tensions
    Russia's Putin tells UAE leader he wants to discuss Iran tensions with him
    Open-source AI models vulnerable to criminal misuse, researchers warn
    Geopolitics loom large over Big Oil earnings as investors seek Venezuela details
    Bank of England weekly repo tops 100 billion pounds for first time
    China relaxes visa rules for UK citizens on PM's trip to Beijing
    Italy's Brembo exceeds 2025 margin target in challenging auto market
    Sterling close to multi-year highs vs dollar, focus shifts to BoE, politics
    EU ministers approve new Iran sanctions after Tehran's crackdown on protests, EU diplomats say
    Samsung, SK Hynix warn of squeezed chip supplies for PCs, phones due to AI boom
    Blackstone to become New World Development's largest shareholder, Bloomberg reports
    View All Finance Posts